GILD  Gilead Sciences Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

-0.66 (-0.63%)

Growth Price

Fairly valued

Stability Price

Overvalued by 58.87%

Company Metrics

  • 14.18 P/E
  • 6.23 P/S
  • 10.11 P/B
  • 7.35 EPS
  • 43.15% Cash ROIC
  • 1.76 Cash Ratio
  • 0 / 0% Dividend
  • 16.62M Avg. Vol.
  • 154.2B Market Cap.

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Gilead Sciences, Inc. Continues To Lead The Hepatitis C Market; Its HCV Drugs ...
Bidness ETC - Feb 28, 2015
The hepatitis C market is currently being ruled by two pharmaceutical giants, Gilead Sciences, Inc. (NASDAQ:GILD) and AbbVie Inc (NYSE:ABBV), with the former company leading the market undisputedly.
With The New Harvoni Promising More Profits, Gilead Sciences, Inc.(NASDAQ ... -
Investors Buy Gilead Sciences on Weakness (GILD) - The Legacy
Gilead Sciences, Inc. HIV Drug TAF Could Replace Current Standard Treatment ...
Bidness ETC - Feb 28, 2015
Gilead Sciences, Inc.'s (NASDAQ:GILD) next-generation HIV drug, called TAF, proved to be safe for use in patients suffering from a mild-to-moderate form of kidney impairment, the company announced Thursday at the Conference on Retroviruses and ...
Gilead Sciences, Inc. (GILD) Announces Results from Phase 3 Trials - InvestCorrectly
Gilead Announces Phase 3 Results for Investigational Once-Daily Single Tablet ... - MarketWatch
Trade of the Day: GILD Stock Just a Few Cents Away From a Breakout - Feb 24, 2015
Gilead Sciences, Inc. (NASDAQ:GILD) - I have been recommending GILD stock since November 2012, when it was trading near $37 (split adjusted).
Analyst Rating Update on Gilead Sciences, Inc. - Stafford Daily
Plummeting Stocks:Gilead Sciences (GILD), Kinder Morgan (KMI), Morgan ... - Techsonian (press release)
Is Gilead Sciences Inc. Stock Cheap Now?
Motley Fool - Feb 18, 2015
The stock market doesn't always make sense or act on rational terms. Sometimes good stocks are sold off for little or no reason.
The Long Case For Gilead Sciences, Inc. (GILD) - Seeking Alpha (registration)
Gilead Sciences, Inc. Price Target Update - Stafford Daily
Gilead Sciences, Inc. Smashes Earnings Estimates
ValueWalk - Feb 3, 2015
Gilead Sciences released its latest earnings report after closing bell tonight, posting adjusted earnings of $2.43 per share on $7.32 billion in revenue, a 137% year over year increase.
Bigger drug discounts put question mark over Gilead's stellar run - Fortune
Hepatitis Quest Moves From C to B Under Ex-Gilead Leaders - Bloomberg
Gilead Sciences, Inc. Announces Harvoni Update; Holds Cash Overseas To ...
Bidness ETC - Feb 27, 2015
Gilead Sciences, Inc. (NASDAQ:GILD), which first shook the hepatitis C market by launching Sovaldi and then followed up with a newer and improved version, Harvoni, for genotype 1 type of hepatitis C virus, announced late Thursday yet another update on ...
Gilead Avoids Billions in U.S. Tax on Its $1000-a-Pill Drug - Bloomberg
Mylan Inc Will Distribute Gilead Sciences, Inc. Sovaldi And Harvoni In India
Bidness ETC - Feb 24, 2015
Mylan Inc (NASDAQ:MYL) announced on Monday it has signed an agreement with Gilead Sciences, Inc. (NASDAQ:GILD), under which the company's Indian subsidiary, Mylan Pharmaceuticals Private Ltd.
Mylan Signs Exclusive Agreement with Gilead Sciences to Distribute Sovaldi ... - PR Newswire (press release)
Mylan signs exclusive agreement with Gilead Sciences - Financial Express
Gilead Sciences, Inc. Sees 1% Increase In Sovaldi, Harvoni New Scripts
Bidness ETC - Feb 20, 2015
Gilead Sciences, Inc. (NASDAQ:GILD) reported a 1% increase in its New Script Numbers (NRx) for Harvoni and Sovaldi. RBC Capital reported a 2% week-over-week decline in Harvoni's Total Script Numbers (TRx) at 8,306.
Gilead Sciences, Inc. Analyst Rating Update - Stafford Daily
Gilead Sciences: How Strong are Hepatitis-C Sales? - Barron's (blog)
Gilead Sciences, Inc. (GILD) Stock's Supernormal Growth Phase Is Over
ETF Daily News - Feb 11, 2015
The cumulative impact of lower prices and gradually eroding market share means that Gilead's explosive growth from Sovaldi is now behind it.
Is Gilead Sciences, Inc. (GILD) Looking Cheap? - InvestCorrectly
Gilead Sciences: 'Significant Reassurance to Skittish Investors' - Barron's (blog)
Updating My Price Target On Gilead Sciences
Seeking Alpha (registration) - Feb 23, 2015
Gilead Sciences (NASDAQ:GILD) has captured the minds and wallets of many due to the ability to cure Hepatitis C. Clinicians marveled at the effectiveness of Sovaldi/Harvoni, its elegant one tablet a day formulation with minimal side effects.